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Directed enzyme prodrug therapy is a chemotherapy strategy that utilises prodrug-activating enzymes 
to activate prodrugs at the tumour location, thus reducing off-target effects. The most commonly 
investigated enzyme for use with the CB1954 prodrug is the NfnB nitroreductase from E.coli. Literature 
states that CB1954 is reduced by NfnB at the 2- or 4-position at a 1:1 ratio; deviation from this ratio 
has been observed in the literature, but not further investigated. The kinetic parameters for the 
genetically-modified enzymes; NfnB-his, NfnB-cys and AuNP-NfnB-cys were assessed and HPLC 
analysis was used to determine the hydroxylamine product ratios formed when reacted with CB1954. 
Time-dependant HPLC studies were carried out to assess how this ratio changes over time. It was shown 
that the hydroxylamine ratio formed by the reduction of CB1954 by a nitroreductase changes over time 
and that this change in ratio relates directly to the kinetics of the reaction. Thus, the hydroxylamine ratio 
measured using HPLC at a given time point was not a true indication of the preference of the 
nitroreductase enzymes during catalysis. These results question how nitroreductases are evaluated in 
terms of the hydroxylamine ratio and it is suspected that this phenomenon may also apply to other 
enzyme/prodrug combinations. 
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1. Introduction 
Cancer is an extremely complex and deadly disease and is one of the leading causes of death worldwide, 
second only to heart disease [1]. Globally cancer is responsible for roughly 30% of deaths each year, 
thus cancer chemotherapy is an area of research of the upmost importance [2]. Current chemotherapy 
still lacks tumour specificity and produces systematic toxicity. Alternative treatment strategies are being 
sought after which are evolving to overcome these limitations, one example being the use of prodrugs 
[3–5]. One potential chemotherapy strategy currently being explored is Directed Enzyme Prodrug 
Therapy (DEPT) [6]. This strategy involves the delivery of prodrug-activating enzymes to a tumour site 
before administering a prodrug, thereby activating the prodrug to its more pharmaceutically active 
products at the cancer site [6], and addressing the aforementioned chemotherapy limitations.  
The prodrug, 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954), is being investigated for use in DEPT 
strategies in combination with prodrug-activating enzymes from the nitroreductase (NTR) family [7–
9]. The prodrug, CB1954 undergoes reduction of either of its nitro groups to a hydroxylamine derivative 
in the presence of an NTR using either Nicotinamide Adenine Dinucleotide (NADH) or Nicotinamide 
Adenine Dinucleotide Phosphate (NADPH) as a cofactor [10,11].  
The most heavily studied NTR for use in DEPT strategies is NfnB from Escherichia coli (E.coli) [8,12–
17]. The NfnB/CB1954 combination has even progressed to the clinical trial stage with positive results 
being seen for both prostate and ovarian cancer cell lines [17,18]. Importantly NfnB has been shown in 
literature (Figure 1) to reduce CB1954 (A) at both the 2-position and 4-position at a ratio of 
approximately 50:50 [19–22]; thus producing an equal mixture of the two hydroxylamine (-NHOH) 
derivatives B and D, each of which has different properties. The 4-hydroxylamine derivative of CB1954 
(D) has been shown to be further reduced by intracellular thioesters such as Acetyl Coenzyme A to 
form a compound (F) that is able to cross-link DNA (Figure 1) [21]. The resulting interstrand cross-
links can cause the DNA strands to break during cell division, leading to apoptosis [23]. In addition, 
the 2-hydroxylamine product of CB1954 (B) is converted intracellularly to the toxic 2-amino (-NH2) 
derivative (C), which has the greatest bystander effect in vitro due to its superior diffusion properties 
[13,20,24,25] to neighbouring cells [8,26,27].  
 
Figure 1. Figure adapted from the work done by P. Race at. al [21] showing the structure 
and reactions of CB1954 (A) with a nitroreductase enzyme and an NAD(P)H cofactor 
showing formation of the hydroxylamine derivatives (B) and (D) and the further reduction to 
the subsequent amine products over time (C) and (E) as well as the formation of the DNA 
cross-linking species (F) formed when the 4-hyroxylamine derivative is reacted with an 
intracellular thioester. 
Previously, enzymes have been selected for use in DEPT strategies based on the ratio of CB1954 
products formed once the prodrug has been reduced by the NTR in question. V. Gwenin et al. 
highlighted a preference for enzymes which preferentially reduce CB1954 at the 4-position and thus 
generate the DNA cross linking species [20], this follows on from the work done by C. Emptage et al. 
where they identified the YfkO NTR from Bacillus Licheniformis as a potential candidate for DEPT 
strategies due to the fact it reduced CB1954 predominately at the 4-position [28]. In addition, Vass et 
al. selected the NfsA NTR due to the fact it preferentially reduces CB1954 at the 2-position and thus 
generated products with a higher bystander effect [25]. 
? 
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It was recently observed within our laboratory, that the CB1954 product ratio changes with time. This 
phenomenon was observed whilst investigating the product ratio for a genetically modified form of 
NfnB, NfnB-cys (NfnB_Ec with a cysteine-tag added via genetic modification) [29–31]. The reason for 
the N-terminal cysteine-tag is for a novel DEPT delivery system being investigated within our group. 
The novel system is based on delivering the modified NTR directly to the tumour site using gold-coated 
magnetic nanoparticles (MNDEPT) [31,32].  
In this study, it was determined whether the observed phenomenon of the change in CB1954 product 
ratio over time was limited to the genetically modified NfnB-cys, or whether this was a phenomenon 
also for the most studied NfnB-his from literature (NfnB_Ec with a histidine-tag added for purification 
purposes). It was also determined whether the product ratio changed when the enzyme was immobilised 
onto colloidal gold nanoparticles (AuNPs).  
Future work following these results, will include investigating the effect of a changing product ratio on 
in vitro cell culture models and to determine how this would possibly affect the novel MNDEPT 
strategy.  
2. Materials and Methods 
2.1 Transformation  
Plasmids of NfnB-his and NfnB-cys that had been prepared previously [31] were sequence verified by 
Eurofins Genomics before being transformed into E.coli competent cells (Rosetta pLysS (Novagen, 
Merck, UK)) and grown on agar plates containing Kanamycin (50 µg/ml). The plasmids pET28a+ 
vector (Novagen, Merck, UK) containing the NTR gene (2 µl) were added to the competent cells (200 
µl) and left on ice for 30 minutes. The samples were then heat shocked at 42oC for 50 seconds before 
being placed back on ice for 2 minutes. The samples were than mixed with sterile Super Optimised 
Broth media containing glucose (S.O.C. media) (500 µl) (2% tryptone, 0.5% yeast extract, 10 mM 
NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4 and 20 mM glucose) before being incubated at 37oC 
for 45 minutes. The sample was then added (125 µl) to sterile agar plates containing Kanamycin (50 
µg/ml) and spread across the plate using a glass spreader. The plates were then left in a 37oC incubator 
overnight and checked the following day for colony growth. 
2.2 Protein expression  
A single colony of bacteria containing the plasmids that had been transformed into E.coli Rosetta pLysS 
(Novagen, Merck, UK) was picked and grown in 5 ml of Luria-Bertani (LB) broth with Kanamycin (50 
µg/ml) overnight at 37°C, this was then transferred in to 500 ml of sterilised LB broth with Kanamycin 
(50 µg/ml) and grown to an OD of 0.6 at 37°C whilst shaking at 180 rpm. After which, Isopropyl β-D-
1-thiogalactopyranoside (IPTG) (2 ml, 100 mM) was added and the cultures were left to grow for 
another 4 hours. Next, the cultures were centrifuged for 10 minutes at 8,000 rpm and 4°C to give pellets 
containing the expressed proteins. 
2.3 Protein purification 
The protein pellets were resuspended in binding buffer (10 ml, potassium phosphate 50 mM, NaCl 400 
mM, Imidazole 10 mM) and sonicated before being centrifuged at 20,000 rpm to pellet any cell debris. 
The yellow supernatant was then purified using metal ion affinity chromatography (Ni2+) (HiTrap 
chelating column, Amersham Biosciences, UK) and eluted with an imidazole gradient, all of the 
fractions were collected in 5 x 1 ml aliquots and kept for analysis using SDS-PAGE. Due to the 
denaturing nature of SDS-PAGE, proteins migrated through the gel as monomers (approximately 28 
kDa for NfnB-cys). Next, the IMAC fractions containing the proteins of interest were incubated for an 
hour with Flavin Mononucleotide (FMN) (5.6 mM, 1 ml) before being purified from imidazole into 
phosphate buffer (50 mM, pH 7.4) using a PD-10 desalting column (Amersham Biosciences, UK). The 
concentration of protein was determined using the Bradford method. The Bradford assay was carried 
out using Quick Start Bradford Dye Reagent from Bio-Rad, UK with Bovine Serum Albumin (BSA) 
being used as the standard for calibration. Protein yield was generally 2-5 mg/ml pure protein [33]. 
2.4 Immobilisation of enzymes to gold nanoparticles 
Immobilisation of the cys-tagged NTRs on to colloidal gold nanoparticles (AuNPs) was done following 
the method described by V. Gwenin et al [31]. Briefly, solutions of 50 nm AuNPs (1.5 nM, Naked Gold, 
BioAssay Works, USA) were incubated with the purified recombinant NfnB-cys enzyme at a ratio of 
270:1 (NTR: AuNP) overnight at 4oC. Conjugation of the NTR to the AuNPs was confirmed using UV-
visible spectroscopy. 
2.5 Enzyme reactivity with CB1954 
The ability of the purified proteins to reduce the CB1954 prodrug was confirmed following the method 
previously described by V. Gwenin et al [31]. Briefly, the proteins were incubated with NADH (300 
μM) and CB1954 (100 μM) in phosphate buffer (PB) (50 mM, pH 7.2) and scanned using UV-visible 
spectroscopy every 90 seconds for 15 minutes. For active NTR/CB1954 combinations, product 
formation was measured at 420 nm [20,31]. 
2.6 CB1954 Kinetics  
All of the kinetics experiments were run using a Thermo Scientific Varioscan 96-well plate microplate 
reader. In each well of the 96-well plate, CB1954 (0.1-10 mM), NADH (4 mM) and PB (50 mM, pH 
7.2) were combined and incubated at 37oC for 3 minutes before the purified NTR (10 μg/ml) was added. 
The Dimethyl sulfoxide (DMSO) solvent concentration was always kept constant at 5% v/v to avoid 
any negative effect [25]. 
To determine the Michaelis-Menten kinetic parameters of CB1954 when using either NfnB-his or 
NfnB-cys, product formation at 420 nm was measured for 2 minutes, of which only the first 20 seconds 
was used to calculate the amount of the CB1954 hydroxylamine product produced. This change in 
product was calculated in Microsoft Excel using the molar extinction coefficient of the hydroxylamine 
products (ε = 1200 M-1 cm-1 at 420 nm) [13,20,21,25,31,34,35]. SigmaPlot 12 (SPSS, Systat Software 
Inc.) and a non-linear regression tool was used to generate a Michaelis-Menten hyperbolic curve and 
kinetic parameters. 
2.7 HPLC  
All experiments were conducted on a HPLC machine (Dionex Ultimate 3000 HPLC system, 
ThermoScientific, USA) using a C18 column for analysis (Waters Spherisorb® 5 µm ODS2 4.6 mm x 
250 mm C18 column, UK). The instrument was run using the following parameters; 50 µl injection 
volume, a fixed column oven temperate of 25oC, a run length of 45 minutes and the UV wavelength for 
detection was 420 nm [20]. The solvent consisted of an acetonitrile/water mixture, beginning with 10% 
acetonitrile and increasing by 1% acetonitrile per minute. After 20 minutes this gradient increases to 
40% acetonitrile per minute, reaching 100% after 22 minutes. Eluents were scanned at 420 nm and 
product peaks were identified by comparisons with all reagents run individually as standards. 
HPLC samples were prepared in a 15 ml falcon tube covered in foil: NADH (60 μl, 20 mM), CB1954 
(10 μl, 100 mM), NTR (116 μg/ml) and made up to 1080 μl with PB (50 mM, pH 7.2). The total reaction 
time was 30 min and consisted of reacting the samples for 15 min after which the samples were degassed 
for 15 minutes.  Next, 700 μl of the de-gassed mixture was placed in a chromacol select 2 ml vial and 
placed in the HPLC machine.  For the time-trial experiments, injections of the same reaction mixture 
were carried out every 45 minutes for another 4.5 hours.  
   
3. Results 
3.1 Protein expression and purification 
The pET28a+ vector contains a his-tag which is inserted into all the recombinant proteins for ease of 
purification using metal ion affinity chromatography (IMAC). NfnB-his is the native E.coli NfnB 
cloned into the pET28a+ vector and which is genetically modified to contain the his-tag, whereas the 
NfnB-cys contains both the his-tag as well as an additional cys-tag (designed by our research group) 
[31] on the N-terminal of the protein which is 6 amino acids long. The purpose of the cys-tag is to allow 
direct binding of the protein to metal surfaces such as gold. In this report, the cys-tag allows direct 
binding to the gold colloid. The weight differences cause small changes in migration on the SDS-PAGE 
as previously described [31]. Both genetically modified proteins were obtained at a yield of up to 5 
mg/ml. 
3.2 Enzymatic reduction of the CB1954 prodrug 
Initially, enzyme reactivity to CB1954 in the presence of NADH was confirmed following the method 
previously described by V. Gwenin et al. [20,31]. Next the kinetic parameters were determined for 









NfnB-his 22.90 4064.43 25.13 0.0062 
NfnB-cys 19.37 5078.37 55.34 0.0109 
AuNP-NfnB-cys 10.89 1108.67 61.85 0.0558 
Table 1. Michaelis-Menten kinetic data obtained for NfnB-his and NfnB-cys and the immobilised 
AuNP-NfnB-cys by varying the concentrations of the CB1954 prodrug in the presence of NADH as the 
cofactor. 
When comparing the Michaelis-Menten kinetic data obtained (Table 1) for NfnB-his and NfnB-cys 
reacting with CB1954 it appears that the incorporation of the cysteine-tag has led to an improvement in 
enzyme kinetic behaviour. NfnB-cys demonstrated a higher turnover than NfnB-his (Kcat = 55.34 S-1 
for NfnB-cys compared to 25.13 S-1 for NfnB-his) as well as greater efficiency in its reaction with 
CB1954 compared to NfnB-his (Kcat/Km = 0.0109 μM-1S-1 compared to 0.0062 μM-1S-1 for NfnB-his) 
despite a slightly lower affinity for the prodrug (Km = 5078.37 μM compared to 4064.43 μM for NfnB-
his). These results are of clinical significance as the poor turnover rate of CB1954 by the NfnB NTR 
has proven to be a major limitation to DEPT strategies [19–21,25,36]. Furthermore, when NfnB-cys 
was immobilised on to colloidal gold nanoparticles it demonstrated an even greater efficiency in its 
reaction with the CB1954 prodrug compared to NfnB-cys free in solution (Kcat/Km = 0.0558 μM-1S-1 
for AuNP-NfnB-cys compared to 0.0109 μM-1S-1 for NfnB-cys) and even greater affinity for the 
CB1954 prodrug than was observed for either NfnB-his or NfnB-cys (Km = 1108.67 μM). This change, 
similar to that which was previously observed by Gwenin et al. [31], is postulated to be due to the cys-
tags orientating the NfnB-cys in such a way that the N-terminus is towards the gold surface and the 
active site facing towards the solvent allowing for a greater interaction with the prodrug and cofactor 
[29,31]. 
3.3 HPLC analysis  
Following the method previously published [20], it was shown that, after 30 minutes of incubation prior 
to injection on the HPLC, NfnB-his produced the two CB1954 hydroxylamine products at a ratio of 
approximately 44:56 (2-NHOH: 4-NHOH; Figure 2), similar to the 50:50 ratio reported previously in 
the literature [19,20,25]. The 2-NHOH eluted from the column at approximately 10 minutes while the 
4-NHOH eluted after approximately 5 minutes. The products formed after further non-enzymatic 
reduction of the hydroxylamine derivatives were detected at 22 min for the 2-NH2 and 15 min for the 
4-NH2 as previously described [20]. 
 
Figure 2. HPLC chromatogram of the reaction mixture in the presence of NfnB-his, measuring 
absorbance at 420 nm. NADH and phosphate buffer were detected at 2-4 minutes, the unreacted 
CB1954 prodrug was detected at 10.5-14 minutes and the DMSO was detected at 22.5-24.5 minutes. 
The 4-hydroxylamine was detected at 5-6 minutes and the corresponding amine was detected at 14.5-
15.5 minutes. The 2-hydroxylamine was detected at 9-10 minutes with the corresponding amine being 
detected at 21-22 minutes. 
Using the same HPLC method with a 30 min incubation time prior to HPLC injection the genetically-
modified NfnB-cys and the NfnB-cys immobilised on to AuNPs (AuNP-NfnB-cys) were analysed and 
the ratios of the CB1954 -NHOH derivatives formed are presented in Table 2. All four metabolites were 
again detected but the quantities differed significantly from that of the NfnB-his. As seen from Table 
2, the hydroxylamine ratios produced by NfnB-cys (32:68) and AuNP-NfnB-cys (13:87) differed 
significantly from the 50:50 ratio generally obtained for NfnB. It was also noted that the 2-NH2:4-NH2 
ratio differed significantly, with a significant increase in the 2-NH2 peak compared to the 4-NH2. 




Table 2. The ratio of the CB1954 hydroxylamine derivatives formed when reacted with different NTRs 
These results together with the kinetic data led to the hypothesis that the NfnB-cys produces the 2- and 
4-hydroxylamines in a shorter reaction time leaving more time for non-enzymatic reduction to the 
respective amines at the point of HPLC analysis. However, if non-enzymatic reduction occurred at the 
same rate for both the 2-NHOH and the 4-NHOH products, then the ratio would have remained the 
same at any given time point. This however, was not the case as can be seen from Table 2. This then 
led to the hypothesis that the 2-NHOH and 4-NHOH metabolites were reduced to their -NH2 derivatives 
at different rates, resulting in an altered 2-NHOH: 4-NHOH ratio.  
In order to investigate the aforementioned hypothesis a time trail of the reaction between NfnB-his and 
CB1954 was conducted (Figure 3 top and bottom) using different time points with the initial injection 
on to the HPLC been done after 30 minutes incubation and each subsequent injection been done after 
an additional 45 minutes. As expected, it was seen that the 2-NHOH and 4-NHOH peaks decreased 
with time and at different rates, while the 2-NH2 and 4-NH2 peaks increased with time and at different 
rates (Figure 3 top and bottom). The results obtained over the duration of the NfnB-his/CB1954 time 
trial can be matched to the results obtained for NfnB-cys and AuNP-NfnB-cys. 
 
 
Figure 3. (Top) HPLC chromatogram of a reaction mixture in the presence of NfnB-his, measuring 
absorbance at 420 nm. The 4-hydroxylamine was detected at 5-6 minutes and the corresponding 
amine was detected at 14.5-15.5 minutes. The 2-hydroxylamine was detected at 9-10 minutes with the 
corresponding amine being detected at 21-22 minutes. (Bottom) A graph showing how each of the 
peak areas corresponding to the hydroxylamine and amine products changes over time as the 
reaction proceeds including labels of where the hydroxylamine ratio for NfnB-his matches those 
obtained for NfnB-cys and AuNP-NfnB-cys. 
These results confirmed the hypothesis that the 2-NHOH and 4-NHOH degraded at different rates which 
affected the hydroxylamine product ratio observed at any given time point. For completion the same 
time dependant HPLC experiment was carried out with NfnB-cys (Figure 4 top and bottom), but the 2’: 
4’ ratio measured at the first reaction time point was already skewed towards the 4’ product as can be 
seen from figure 4 (Bottom, 30 min). To determine whether the NfnB-cys had a ratio closer to 50:50 at 
an earlier time point, an HPLC was run after a 15 min reaction time, which showed the NfnB-cys to 
produce a 42:58 ratio as expected (data not shown) and following the same trend as that observed for 
the NfnB-his.  
 
 
Figure 4. (Top) HPLC chromatogram of a reaction mixture in the presence of NfnB-cys, measuring 
absorbance at 420 nm. The 4-hydroxylamine was detected at 5-6 minutes and the corresponding 
amine was detected at 14.5-15.5 minutes. The 2-hydroxylamine was detected at 9-10 minutes with the 
corresponding amine being detected at 21-22 minutes. (Bottom) A graph showing how each of the 




In this report, two genetically modified nitroreductase enzymes (NfnB-his and NfnB-cys) were 
evaluated with regards to their enzyme activity and hydroxylamine product ratio after reaction with the 
CB1954 prodrug. Generally, the bacterial nitroreductases which reduce the CB1954 prodrug, produce 
two products, the 2-NHOH and the 4-NHOH toxic metabolites. Since the recognition of their usefulness 
in chemotherapy, Nitroreductases have been characterised based on their ability to produce either one 
or the other metabolite. The 4-NHOH has the greatest cytotoxicity. Thus, nitroreductases producing the 
4-NHOH as the major product, have had preference over those which produce predominantly the 2-
NHOH metabolite. Both the 2-NHOH and 4-NHOH can be non-enzymatically reduced to the 
corresponding amines, which are slightly less toxic but have good diffusion properties (bystander 
effect).  
The initial purpose of this investigation was to prove that the cys-tag added to the NfnB-his (to allow 
direct immobilisation onto metal nanoparticles) did not have a negative effect on enzyme kinetics or on 
the CB1954 product ratio. From literature and within our laboratory, NfnB-his has always shown to 
have a less optimal turn over for the CB1954 and poor efficiency. Furthermore, the NfnB-his NTR is 
reported in the literature to produce the 2-NHOH and 4-NHOH in equimolar amounts; this has been 
verified in our own work using this enzyme as NfnB-his was shown to produce the NHOH products in 
a ratio of 44:56 after a 30 minute reaction time (Figure 2). Unfortunately due to differences in 
experimental parameters found in the literature [19,24,25,37], it is not possible to directly compare the 
ratios produced at a given time point however the data produced here is validated by the fact that the 
50:50 ratio observed in the literature can be replicated after conducting the HPLC after a 30 minute 
reaction time. 
Firstly, the kinetic parameters for the genetically modified enzymes were determined regarding their 
reaction with the CB1954 prodrug in the presence of the NADH cofactor (Table 1). Surprisingly the 
cys-tag enzyme had superior efficiency for prodrug conversion compared to the his-tag counterpart, 
which was further increased by immobilisation onto gold nanoparticles. These results could be 
explained in that the cys-tag altered the three-dimensional structure such that the active site became 
more available to react with the CB1954 prodrug and that immobilisation onto the gold surface, further 
optimised the active site availability, resulting in increased turn-over and efficiency of the enzyme.  
Following these results HPLC analysis was done to determine whether the NfnB-cys produced the same 
CB1954 product ratio as the NfnB-his reported in literature. Contrary to what was expected the product 
ratio produced by the NfnB-cys/CB1954 combination was significantly different to the 50:50 ratio 
obtained for NfnB-his.  It became necessary to determine whether the genetic modification of the NfnB-
cys NTR had led to it producing a different ratio of the CB1954 NHOH derivatives or if this was due 
to the difference in the kinetics between NfnB-his and NfnB-cys when reacted with the CB1954. It was 
shown that the NfnB-cys had a superior turnover rate of CB1954 compared to the NfnB-his and thus it 
would be able to reduce more of the prodrug over the same period. A time trial we next conducted and 
it was notable from the time trial that when initially tested after 30 minutes the hydroxylamine ratio 
obtained for NfnB-his was 44:56 but after a further 45 minutes the ratio had changed to 30:70, closely 
matching the result obtained for NfnB-cys after 30 minutes (32:68) and after an additional 45 minutes 
that ratio had reached 17:83 which closely matched the result obtained for AuNP-NfnB-cys after 30 
minutes (13:87).  
A similar discrepancy in the product ratio to this has been seen previously in the cell culture literature 
with Vass et al [25] noting that when they analysed the supernatant of SK-OV-3 cells treated with the 
NfnB NTR and CB1954 that the ratio of the NHOH products released into the cell medium had deviated 
from the expected 1:1 ratio and the reaction had seemingly produced more of the 2-NHOH product. 
They proposed that this was caused by the higher reactivity of the 4-NHOH product intracellularly 
compared to the 2-NHOH product causing the 4-NHOH to have reacted prior to analysis thus boosting 
the product ratio in favour of the 2-NHOH. 
Following the same line of thought as Vass et al., it was noted that the degradation products, the 2-NH2 
and 4-NH2, also differed between the NfnB-his and NfnB-cys enzymes. The further reduction of the 
NHOH metabolites to their -NH2 derivatives can be classified as being a non-enzymatic reduction due 
to the fact that this reduction continues to occur after the NTR has exhausted its supply of NADH and 
thus cannot be responsible for this reaction. Combing the kinetic data with the HPLC result led to the 
hypothesis that the 2-NHOH and 4-NHOH were reduced to the 2-NH2 and 4-NH2 at different rates, 
resulting in an altered 2-NHOH: 4-NHOH ratio being observed for the NfnB-cys and could also possibly 
explain the discrepancies seen in literature. The time trial performed with NfnB-his, NfnB-cys and 
CB1954 showed for the first time that the 2-NHOH: 4-NHOH ratio obtained was dependent on the 
reaction time, not on the enzyme preference for a particular -NO2 group. Due to the cost implications 
of running a time dependant analysis of the AuNP-NfnB-cys with CB1954, it was decided that this 
experiment would not be carried out.  
Based on the data generated for the NfnB-his and NfnB-cys free in solution, it became apparent that the 
reason behind the changes in ratio over time was that the further reduction of the CB1954 -NHOH 
products (Figure. 1; B and D) to their corresponding -NH2 derivatives (Figure. 1; C and E) proceeded 
more readily at the 2’ position compared to the 4’ position. This resulted in the 2-NHOH being more 
readily reduced and the ratio of hydroxylamines derivatives increases in favour of the 4-NHOH over 
time. Previously it had been believed that the observed shift in hydroxylamine product ratio for 
nitroreductase enzymes in general was caused by the intracellular reactivity of the 4-NHOH product 
however this does not seem to be the case here as no thioesters were present to facilitate that further 
reaction [25]. 
5. Conclusions 
This new insight into the change in ratio with time will directly relate to future cell culture experiments 
due to the different properties of the two products. Furthermore, the revelations about the changing 
hydroxylamine product ratio over time could cause some NTRs that have been previously been 
discounted for use in DEPT treatments due to the product ratio they produce to be reconsidered as the 
assessment of NTR product ratios was likely done at fixed time points and therefore would not be a true 
representation of the full system and products that would be produced over the course of an 
NTR/CB1954 treatment. 
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